BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x. [PMID: 21689610 DOI: 10.1016/j.cld.2011.03.006] [Cited by in Crossref: 324] [Cited by in F6Publishing: 362] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Wu J, Wu Q, Zhang X, Lin S, Ran W, Zhu L, Tang C, Wang X. Sex steroid axes in determining male predominance in hepatocellular carcinoma. Cancer Lett 2023;555:216037. [PMID: 36563929 DOI: 10.1016/j.canlet.2022.216037] [Reference Citation Analysis]
2 Qiu X, Xu H, Wang K, Gao F, Xu X, He H. P-21 Activated Kinases in Liver Disorders. Cancers (Basel) 2023;15. [PMID: 36672500 DOI: 10.3390/cancers15020551] [Reference Citation Analysis]
3 Onikanni SA, Lawal B, Bakare OS, Ajiboye BO, Ojo OA, Farasani A, Kabrah SM, Batiha GE, Conte-Junior CA. Cancer of the Liver and its Relationship with Diabetes mellitus. Technol Cancer Res Treat 2022;21:15330338221119743. [PMID: 36533882 DOI: 10.1177/15330338221119743] [Reference Citation Analysis]
4 Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, Müller M, Kandulski A. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines 2022;10. [PMID: 36551958 DOI: 10.3390/biomedicines10123202] [Reference Citation Analysis]
5 Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022;23. [PMID: 36430594 DOI: 10.3390/ijms232214117] [Reference Citation Analysis]
6 Hussein AM, El-Beih NM, Swellam M, El-Hussieny EA. Pomegranate juice and punicalagin-mediated chemoprevention of hepatocellular carcinogenesis via regulating miR-21 and NF-κB-p65 in a rat model. Cancer Cell Int 2022;22:333. [PMID: 36324170 DOI: 10.1186/s12935-022-02759-9] [Reference Citation Analysis]
7 Giuffrè M, Zuliani E, Visintin A, Tarchi P, Martingano P, Pizzolato R, Bonazza D, Masutti F, Moretti R, Crocè LS. Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience. Diagnostics 2022;12:2517. [DOI: 10.3390/diagnostics12102517] [Reference Citation Analysis]
8 Ding H, Fawad M, Xu X, Hu B. A framework for identification and classification of liver diseases based on machine learning algorithms. Front Oncol 2022;12:1048348. [DOI: 10.3389/fonc.2022.1048348] [Reference Citation Analysis]
9 Nguyen ALT, Blizzard CL, Yee KC, Palmer AJ, de Graaff B. Survival of primary liver cancer for people from culturally and linguistically diverse backgrounds in Australia. Cancer Epidemiol 2022;81:102252. [PMID: 36116274 DOI: 10.1016/j.canep.2022.102252] [Reference Citation Analysis]
10 Zhang M, He DC, Chung A. Identification of transcriptional landscapes and functions of the inhibition of ARHGEF2 in hepatocellular carcinoma cells.. [DOI: 10.1101/2022.08.18.504433] [Reference Citation Analysis]
11 Liu T, Zhang Q, Xiao X, Wang Y, Ma X, Song M, Zhang Q, Cao L, Shi H. High salt intake combined with hypertension elevated the risk of primary liver cancer: a prospective cohort study. Front Oncol 2022;12:916583. [DOI: 10.3389/fonc.2022.916583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Patsenker E, Thangapandi VR, Knittelfelder O, Palladini A, Hefti M, Beil-Wagner J, Rogler G, Buch T, Shevchenko A, Hampe J, Stickel F. The Pnpla3 Variant I148M Reveals Protective Effects Towards Hepatocellular Carcinoma in Mice via Restoration of Omega-3 Polyunsaturated Fats. J Nutr Biochem 2022;:109081. [PMID: 35691594 DOI: 10.1016/j.jnutbio.2022.109081] [Reference Citation Analysis]
13 Hyams TC, Luo L, Hair B, Lee K, Lu Z, Seminara D. Machine Learning Approach to Facilitate Knowledge Synthesis at the Intersection of Liver Cancer, Epidemiology, and Health Disparities Research. JCO Clin Cancer Inform 2022;6:e2100129. [PMID: 35623021 DOI: 10.1200/CCI.21.00129] [Reference Citation Analysis]
14 Gou Y, Zheng X, Li W, Deng H, Qin S. Polysaccharides Produced by the Mushroom Trametes robiniophila Murr Boosts the Sensitivity of Hepatoma Cells to Oxaliplatin via the miR-224-5p/ABCB1/P-gp Axis. Integr Cancer Ther 2022;21:153473542210902. [DOI: 10.1177/15347354221090221] [Reference Citation Analysis]
15 Patil SA, Mayor JA, Kaplan RS. Citrate transporter inhibitors: possible new anticancer agents. Future Med Chem 2022. [PMID: 35357238 DOI: 10.4155/fmc-2021-0341] [Reference Citation Analysis]
16 Tandoh KZ, Quaye O. Genetic associations in chronic hepatitis B infection: toward developing polygenic risk scores. Future Microbiol 2022. [PMID: 35332782 DOI: 10.2217/fmb-2021-0176] [Reference Citation Analysis]
17 Zhou X, Zhang T, Sun Y, Li C, Ding X, Zhu Y, Li L, Fan Z. Systematic Review and Meta-analysis: Association of Aspirin With Incidence of Hepatocellular Carcinoma. Front Pharmacol 2022;13:764854. [PMID: 35300300 DOI: 10.3389/fphar.2022.764854] [Reference Citation Analysis]
18 Luu MH, Walsum TV, Mai HS, Franklin D, Nguyen TTT, Le TM, Moelker A, Le VK, Vu DL, Le NH, Tran QL, Chu DT, Trung NL. Automatic scan range for dose-reduced multiphase CT imaging of the liver utilizing CNNs and Gaussian models. Med Image Anal 2022;78:102422. [PMID: 35339951 DOI: 10.1016/j.media.2022.102422] [Reference Citation Analysis]
19 Zhang J, Luo S, Qiang Y, Tian Y, Xiao X, Li K, Li X, Tsui P. Edge Constraint and Location Mapping for Liver Tumor Segmentation from Nonenhanced Images. Computational and Mathematical Methods in Medicine 2022;2022:1-15. [DOI: 10.1155/2022/1248311] [Reference Citation Analysis]
20 Shi J, Liu J, Tu X, Li B, Tong Z, Wang T, Zheng Y, Shi H, Zeng X, Chen W, Yin W, Fang W. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy. J Immunother Cancer 2022;10:e003133. [PMID: 35101942 DOI: 10.1136/jitc-2021-003133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA, Gharzouzi E, Dean M, McGlynn KA, Ramírez-Zea M. Aflatoxin and the Etiology of Liver Cancer and Its Implications for Guatemala. World Mycotoxin J 2021;14:305-17. [PMID: 35096197 DOI: 10.3920/wmj2020.2641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Abdelrahim M, Victor D, Esmail A, Kodali S, Graviss EA, Nguyen DT, Moore LW, Saharia A, McMillan R, Fong JN, Uosef A, Elshawwaf M, Heyne K, Ghobrial RM. Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience. Cancers (Basel) 2022;14:650. [PMID: 35158918 DOI: 10.3390/cancers14030650] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
23 Romero S, Holmes JA. Editorial: hepatocellular carcinoma risk prediction models following DAA-mediated SVR-more evidence needed. Aliment Pharmacol Ther 2022;55:135-6. [PMID: 34907553 DOI: 10.1111/apt.16695] [Reference Citation Analysis]
24 Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 2021;16:e0261878. [PMID: 34962955 DOI: 10.1371/journal.pone.0261878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kronenfeld JP, Goel N. An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1209-19. [PMID: 34611524 DOI: 10.2147/JHC.S284430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
26 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Duan X, Cai Y, He T, Shi X, Zhao J, Zhang H, Shen Y, Zhang H, Zhang H, Duan W, Jiang B, Mao X. The effect of the TP53 and RB1 mutations on the survival of hepatocellular carcinoma patients with different racial backgrounds. J Gastrointest Oncol 2021;12:1786-96. [PMID: 34532128 DOI: 10.21037/jgo-21-312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Songjang W, Nensat C, Pongcharoen S, Jiraviriyakul A. The role of immunogenic cell death in gastrointestinal cancer immunotherapy (Review). Biomed Rep 2021;15:86. [PMID: 34512974 DOI: 10.3892/br.2021.1462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Roy S, Banerjee P, Ekser B, Bayless K, Zawieja D, Alpini G, Glaser SS, Chakraborty S. Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer. Am J Pathol 2021;191:2052-63. [PMID: 34509441 DOI: 10.1016/j.ajpath.2021.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Gupta S, Khan S, Kawka M, Gujjuri R, Chau I, Starling N, Cunningham D, Jiao LR, Gall T. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34402366 DOI: 10.1080/17474124.2021.1967144] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
33 Melaram R. Environmental Risk Factors Implicated in Liver Disease: A Mini-Review. Front Public Health 2021;9:683719. [PMID: 34249849 DOI: 10.3389/fpubh.2021.683719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Harding-Theobald E, Yao FYK, Mehta N. Neutrophil-to-Lymphocyte Ratio Predicts High-Risk Explant Features and Waitlist Survival But Is Not Independently Associated With Recurrence or Survival Following Liver Transplantation for Hepatocellular Carcinoma. Liver Transpl 2021;27:818-29. [PMID: 33570786 DOI: 10.1002/lt.26010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
35 Galal G, Tammam H, Abdel Aal A, Fahmy N, Sheneef A, Ahmed N, Zaghloul A. Role of Lymphotoxin-α Gene Polymorphism in Hepatitis C Virus-Related Chronic Liver Disorders. Infect Drug Resist 2021;14:1921-30. [PMID: 34079302 DOI: 10.2147/IDR.S306879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Yu S, Wang H, Hu T, Yu C, Liu H, Chen X, Jiang J, Deng M. Disease burden of liver cancer attributable to specific etiologies in China from 1990 to 2019: An age-period-cohort analysis. Sci Prog 2021;104:368504211018081. [PMID: 34003688 DOI: 10.1177/00368504211018081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Munakarmi S, Shrestha J, Shin HB, Lee GH, Jeong YJ. 3,3'-Diindolylmethane Suppresses the Growth of Hepatocellular Carcinoma by Regulating Its Invasion, Migration, and ER Stress-Mediated Mitochondrial Apoptosis. Cells 2021;10:1178. [PMID: 34066056 DOI: 10.3390/cells10051178] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
39 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
40 Hassan HM, Isovic M, Kolendowski B, Bauer-Maison N, Onabote O, Cecchini M, Haig A, Maleki Vareki S, Underhill TM, Torchia J. Loss of Thymine DNA Glycosylase Causes Dysregulation of Bile Acid Homeostasis and Hepatocellular Carcinoma. Cell Rep 2020;31:107475. [PMID: 32268085 DOI: 10.1016/j.celrep.2020.03.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
41 Tangjarusritaratorn T, Tangjittipokin W, Kunavisarut T. Incidence and Survival of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Cirrhosis Who Were Treated with and without Metformin. Diabetes Metab Syndr Obes 2021;14:1563-74. [PMID: 33859487 DOI: 10.2147/DMSO.S295753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Mohamed AA, Abdel-rahman AA, Saad S, Mousa S, Tantawi O, Zahran FE, Shafik NF, Elshimy RA, Alkhalegy AA, Kandil A, Ahmed R, Khalil M, Soliman MY, Abo-amer YE, Abd-elsalam S. HLA-DQ Gene Polymorphisms Associated with Hepatitis B Virus in Patients with Hepatocellular Carcinoma Progression. CCTR 2021;17:75-81. [DOI: 10.2174/1573394716666200712151208] [Reference Citation Analysis]
43 Zhang D, Tang W, Weng S, Zhang N, Luo T, Shen X, Dong L. Integrated in silico‐in vitro analysis of systematic kinase gatekeeper mutation effects on pan‐kinase inhibitors in targeted liver cancer therapy. J Chin Chem Soc 2021;68:647-56. [DOI: 10.1002/jccs.202000241] [Reference Citation Analysis]
44 Kang BY, Hur W, Kim SM, Kim S, Lee J, Tak E, Kim WJ, Chun HJ, Yoon SK. Phenylboronic acid conjugated to doxorubicin nanocomplexes as an anti-cancer drug delivery system in hepatocellular carcinoma. Nanomedicine 2021;34:102389. [PMID: 33753281 DOI: 10.1016/j.nano.2021.102389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
46 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
47 Kayamba V. Nutrition and upper gastrointestinal cancers: An overview of current understandings. Seminars in Cancer Biology 2021. [DOI: 10.1016/j.semcancer.2021.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
48 Tiwari A, Modi SJ, Gabhe SY, Kulkarni VM. Evaluation of piperine against cancer stem cells (CSCs) of hepatocellular carcinoma: Insights into epithelial-mesenchymal transition (EMT). Bioorg Chem 2021;110:104776. [PMID: 33743225 DOI: 10.1016/j.bioorg.2021.104776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Rai SPV, Kumar VK, Basavaiah SH, Sreeram S, Gopal S, Tantry BV. Efficacy and Validity of Image-Guided Percutaneous Fine Needle Aspiration and Core Biopsy of Liver Pathologies: Saga of Focal Hepatic Lesions from the Nodule to the Needle to the Slide. J Cytol 2021;38:21-30. [PMID: 33935388 DOI: 10.4103/JOC.JOC_70_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Wei J, Fang D. Endoplasmic Reticulum Stress Signaling and the Pathogenesis of Hepatocarcinoma. Int J Mol Sci 2021;22:1799. [PMID: 33670323 DOI: 10.3390/ijms22041799] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
51 Bhowmick S, Singh V, Jash S, Lal M, Sinha Roy S. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion 2021;58:24-37. [PMID: 33581332 DOI: 10.1016/j.mito.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
52 Diallo I, Ndiaye B, Touré M, Sow A, Mbengue A, Diawara PS, Gning SB, Mbaye PS, Fall F, Mbengue M. Hepatocellular carcinoma in Senegal: epidemiological, clinical and etiological aspects about 229 cases at Hôpital Principal de Dakar. Pan Afr Med J 2021;38:99. [PMID: 33889265 DOI: 10.11604/pamj.2021.38.99.25195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
53 Rashdan HRM, Shehadi IA, Abdelmonsef AH. Synthesis, Anticancer Evaluation, Computer-Aided Docking Studies, and ADMET Prediction of 1,2,3-Triazolyl-Pyridine Hybrids as Human Aurora B Kinase Inhibitors. ACS Omega 2021;6:1445-55. [PMID: 33490804 DOI: 10.1021/acsomega.0c05116] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
54 Chen CY, Wang TY, Chen WM, Chen KH, Yang YH, Chen PC, Chen VC. Bilateral oophorectomy and the risk of hepatocellular carcinoma in women with hepatitis C: A population-based study. Maturitas 2021;146:11-7. [PMID: 33722359 DOI: 10.1016/j.maturitas.2020.12.006] [Reference Citation Analysis]
55 Bhatti ABH. Hepatocellular Carcinoma in Pakistan: An Update. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_25] [Reference Citation Analysis]
56 Shaikh S. PET-CT in the Organ Transplantation. PET-CT in Infection and Inflammation 2021. [DOI: 10.1007/978-981-15-9801-2_19] [Reference Citation Analysis]
57 Temraz S, Taher AT. An Overview of Hepatocellular Carcinoma (HCC) in Lebanon: A Focus on Hepatitis B- and Thalassemia-Related HCC. Liver Cancer in the Middle East 2021. [DOI: 10.1007/978-3-030-78737-0_24] [Reference Citation Analysis]
58 Tohra S, Duseja A, Taneja S, Kalra N, Gorsi U, Behera A, Kaman L, Dahiya D, Sahu S, Sharma B, Singh V, Dhiman RK, Chawla Y. Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis. J Clin Exp Hepatol 2021;11:682-90. [PMID: 34866847 DOI: 10.1016/j.jceh.2021.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
59 Literatur. ELSEVIER ESSENTIALS Onkologie 2021. [DOI: 10.1016/b978-3-437-21432-5.00020-0] [Reference Citation Analysis]
60 Thandra KC, Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. Epidemiology of non-alcoholic fatty liver disease and risk of hepatocellular carcinoma progression. Clin Exp Hepatol 2020;6:289-94. [PMID: 33511275 DOI: 10.5114/ceh.2020.102153] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
61 Campigotto M, Giuffrè M, Colombo A, Visintin A, Aversano A, Budel M, Masutti F, Abazia C, Crocé LS. Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature. World J Hepatol 2020; 12(12): 1239-1257 [PMID: 33442451 DOI: 10.4254/wjh.v12.i12.1239] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
62 Li Y, Han Q, Zhao H, Guo Q, Zhang J. Napabucasin Reduces Cancer Stem Cell Characteristics in Hepatocellular Carcinoma. Front Pharmacol 2020;11:597520. [PMID: 33343368 DOI: 10.3389/fphar.2020.597520] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
63 Akhaladze DG, Rabaev GS. Pediatric hepatocellular carcinoma - the main differences from adult patients. Ann hir gepatol 2020;25:85-94. [DOI: 10.16931/1995-5464.2020485-94] [Reference Citation Analysis]
64 Berman ZT, Newton I. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma. Semin Intervent Radiol 2020;37:441-7. [PMID: 33328699 DOI: 10.1055/s-0040-1719185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
65 Siyin ST, Liu T, Li W, Yao N, Xu G, Qu J, Chen Y. A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer. BMC Cancer 2020;20:1168. [PMID: 33256656 DOI: 10.1186/s12885-020-07665-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Skalny T, Kleczka A, Kubina R, Owczarzy A, Wyszyńska M, Kabała-dzik A. Assessment of antiproliferative, cytotoxic and proapoptotic properties of selected flavonoids in relation to liver cancers – in vitro studies. Ann Acad Med Siles 2020;74:181-190. [DOI: 10.18794/aams/116016] [Reference Citation Analysis]
67 Siddiqui MA, Siddiqui HH, Mishra A, Usmani A. Evaluation of Cytotoxic Activity of Lavandula stoechas Aerial Parts Fractions against HepG2 Cell Lines. CBC 2020;16:1281-9. [DOI: 10.2174/1573407215666190916102325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 He G, Fu S, Li Y, Li T, Mei P, Feng L, Cai L, Cheng Y, Zhou C, Tang Y, Huang W, Liu H, Cen B, Pan M, Gao Y. TCGA and ESTIMATE data mining to identify potential prognostic biomarkers in HCC patients. Aging (Albany NY) 2020;12:21544-58. [PMID: 33177245 DOI: 10.18632/aging.103943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
69 Lim HK, Jeffrey GP, Ramm GA, Soekmadji C. Pathogenesis of Viral Hepatitis-Induced Chronic Liver Disease: Role of Extracellular Vesicles. Front Cell Infect Microbiol 2020;10:587628. [PMID: 33240824 DOI: 10.3389/fcimb.2020.587628] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
70 Yoneoka G, Bozhilov K, Wong LL. Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma. Hepatoma Res 2020;6:67. [PMID: 33134551 DOI: 10.20517/2394-5079.2020.57] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
71 Aly A, Malangone-Monaco E, Noxon V, Henriques C, Benavente F, Kim A. Treatment patterns and direct medical costs among patients with advanced hepatocellular carcinoma. Curr Med Res Opin 2020;36:1813-23. [PMID: 32969741 DOI: 10.1080/03007995.2020.1824899] [Reference Citation Analysis]
72 Liu T, Siyin ST, Yao N, Xu G, Chen YT, Duan N, Li W, Qu J, Liu S. Risk of primary liver cancer associated with gallstones and cholecystectomy: A competing risks analysis. Medicine (Baltimore) 2020;99:e22428. [PMID: 32991479 DOI: 10.1097/MD.0000000000022428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Loftfield E, Rothwell JA, Sinha R, Keski-Rahkonen P, Robinot N, Albanes D, Weinstein SJ, Derkach A, Sampson J, Scalbert A, Freedman ND. Prospective Investigation of Serum Metabolites, Coffee Drinking, Liver Cancer Incidence, and Liver Disease Mortality. J Natl Cancer Inst 2020;112:286-94. [PMID: 31168595 DOI: 10.1093/jnci/djz122] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
74 Yadav S, Kashaninejad N, Nguyen NT. RhoA and Rac1 in Liver Cancer Cells: Induction of Overexpression Using Mechanical Stimulation. Micromachines (Basel) 2020;11:E729. [PMID: 32731493 DOI: 10.3390/mi11080729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
75 Wang J, Li J, Chen L, Fan Z, Cheng J. MicroRNA-499 Suppresses the Growth of Hepatocellular Carcinoma by Downregulating Astrocyte Elevated Gene-1. Technol Cancer Res Treat 2020;19:1533033820920253. [PMID: 32691684 DOI: 10.1177/1533033820920253] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
76 Wang Z, Duan Y, Zhang J, Lv Y, Wu S, Cheng M, Bhagavathula AS, Aldhaleei WA, Clark C, Huo Z. Preoperative antiviral therapy and microvascular invasion in hepatitis B virus-related hepatocellular carcinoma: A meta-analysis. Eur J Pharmacol 2020;883:173382. [PMID: 32693099 DOI: 10.1016/j.ejphar.2020.173382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Sun M, Cui H, Liang M, Wang W, Wang Y, Liu X, Liu S, Cao L. Perceived dietary salt intake and the risk of primary liver cancer: a population-based prospective study. J Hum Nutr Diet 2020;33:833-40. [PMID: 32548912 DOI: 10.1111/jhn.12761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
78 Wu YJ, Wei WC, Dai GF, Su JH, Tseng YH, Tsai TC. Exploring the Mechanism of Flaccidoxide-13-Acetate in Suppressing Cell Metastasis of Hepatocellular Carcinoma. Mar Drugs 2020;18:E314. [PMID: 32549236 DOI: 10.3390/md18060314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Li J, Liu M. The Carcinogenicity of Aflatoxin B1. Aflatoxin B1 Occurrence, Detection and Toxicological Effects 2020. [DOI: 10.5772/intechopen.88353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
80 Zhang H. Mechanisms of mutagenesis induced by DNA lesions: multiple factors affect mutations in translesion DNA synthesis. Crit Rev Biochem Mol Biol 2020;55:219-51. [PMID: 32448001 DOI: 10.1080/10409238.2020.1768205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
81 Liu L, He C, Liu H, Wang G, Lv Z, Ni Y, Mou L, Zhan Y, Liu J. Transcriptomic profiling of long non-coding RNAs in non-virus associated hepatocellular carcinoma. Cell Biochem Biophys 2020;78:465-74. [PMID: 32405957 DOI: 10.1007/s12013-020-00915-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kangas-Dick A, Gall V, Hilden P, Turner A, Greenbaum A, Sesti J, Paul S, Carpizo D, Kennedy T, Sadaria Grandhi M, Alexander HR, Wang S, Geffner S, August D, Langan RC. Disparities in utilization of services for racial and ethnic minorities with hepatocellular carcinoma associated with hepatitis C. Surgery 2020;168:49-55. [PMID: 32414566 DOI: 10.1016/j.surg.2020.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Xiao H, Li X, Zheng C, Liu Q, Sun C, Huang J, Wang Y, Yuan Y. Intracellular pH-responsive polymeric micelle for simultaneous chemotherapy and MR imaging of hepatocellular carcinoma. J Nanopart Res 2020;22. [DOI: 10.1007/s11051-020-04821-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
84 Shawon MA, Yousuf MAK, Raheem E, Ahmed S, Dipti TT, Hoque MR, Taniguchi H, Karim MR. Epidemiology, clinical features, and impact of food habits on the risk of hepatocellular carcinoma: A case-control study in Bangladesh. PLoS One 2020;15:e0232121. [PMID: 32339207 DOI: 10.1371/journal.pone.0232121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
85 Cao Y, Lv W, Ding W, Li J. Sevoflurane inhibits the proliferation and invasion of hepatocellular carcinoma cells through regulating the PTEN/Akt/GSK‑3β/β‑catenin signaling pathway by downregulating miR‑25‑3p. Int J Mol Med 2020;46:97-106. [PMID: 32319540 DOI: 10.3892/ijmm.2020.4577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
86 Wu MY, Tang YP, Liu JJ, Liang R, Luo XL. Global transcriptomic study of circRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. J Cancer 2020;11:2993-3001. [PMID: 32226514 DOI: 10.7150/jca.39854] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
87 Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α. Oncogene 2020;39:2863-76. [PMID: 32034309 DOI: 10.1038/s41388-020-1190-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
88 Tipanee J, Di Matteo M, Tulalamba W, Samara-Kuko E, Keirsse J, Van Ginderachter JA, Chuah MK, VandenDriessche T. Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons. Mol Ther Nucleic Acids 2020;19:1309-29. [PMID: 32160703 DOI: 10.1016/j.omtn.2020.01.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
89 Hassanipour S, Vali M, Gaffari-Fam S, Nikbakht HA, Abdzadeh E, Joukar F, Pourshams A, Shafaghi A, Malakoutikhah M, Arab-Zozani M, Salehiniya H, Mansour-Ghanaei F. The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis. EXCLI J 2020;19:108-30. [PMID: 32038120 DOI: 10.17179/excli2019-1842] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
90 Liu Y, Zhang J, Chen Y, Sohel H, Ke X, Chen J, Li YX. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging (Albany NY) 2020;12:204-23. [PMID: 31905170 DOI: 10.18632/aging.102610] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
91 Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho GF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-351. [PMID: 32067677 DOI: 10.1016/j.annonc.2019.12.001] [Cited by in Crossref: 70] [Cited by in F6Publishing: 81] [Article Influence: 17.5] [Reference Citation Analysis]
92 Simon J, Ouro A, Ala-Ibanibo L, Presa N, Delgado TC, Martínez-Chantar ML. Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover. Int J Mol Sci 2019;21:E40. [PMID: 31861664 DOI: 10.3390/ijms21010040] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
93 Wang S, Yu Y, Ryan PM, Dang M, Clark C, Kontogiannis V, Rahmani J, Varkaneh HK, Salehisahlabadi A, Day AS, Zhang Y. Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol Res 2020;151:104585. [PMID: 31816436 DOI: 10.1016/j.phrs.2019.104585] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
94 Ye L, Zhang X, Xu Q, Cai Y, Gao W, Chen W. Anti-tumor activities and mechanism study of α-pinene derivative in vivo and in vitro. Cancer Chemother Pharmacol 2020;85:367-77. [PMID: 31797046 DOI: 10.1007/s00280-019-03997-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
95 Kim BR, Ha J, Lee S, Park J, Cho S. Anti-cancer effects of ethanol extract of Reynoutria japonica Houtt. radix in human hepatocellular carcinoma cells via inhibition of MAPK and PI3K/Akt signaling pathways. Journal of Ethnopharmacology 2019;245:112179. [DOI: 10.1016/j.jep.2019.112179] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
96 A. Sherif Z. The Rise in the Prevalence of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Nonalcoholic Fatty Liver Disease - An Update 2019. [DOI: 10.5772/intechopen.85780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
97 Wu Q, Wang X, Pham K, Luna A, Studzinski GP, Liu C. Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination. J Steroid Biochem Mol Biol 2020;197:105524. [PMID: 31704246 DOI: 10.1016/j.jsbmb.2019.105524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
98 Özeren N, Kisacam MA, Ozan Kocamuftuoglu G, Kaya N, Ozan ST. The protective role of oleuropein against diethylnitrosamine and phenobarbital induced damage in rats. Turkish Journal of Biochemistry 2019;44:714-721. [DOI: 10.1515/tjb-2018-0166] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
99 Salvatore M, Jeon J, Meza R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016. Cancer Causes Control 2019;30:1377-88. [PMID: 31606852 DOI: 10.1007/s10552-019-01237-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
100 Wang XK, Liao XW, Yang CK, Yu TD, Liu ZQ, Gong YZ, Huang KT, Zeng XM, Han CY, Zhu GZ, Qin W, Peng T. Diagnostic and prognostic biomarkers of Human Leukocyte Antigen complex for hepatitis B virus-related hepatocellular carcinoma. J Cancer 2019;10:5173-90. [PMID: 31602270 DOI: 10.7150/jca.29655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
101 Mchugh KE, Policarpio-nicolas Md MLC, Reynolds JP. Fine-needle aspiration of the liver: a 10-year single institution retrospective review. Human Pathology 2019;92:25-31. [DOI: 10.1016/j.humpath.2019.07.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
102 Li Y, Lu J, Chen Q, Han S, Shao H, Chen P, Jin Q, Yang M, Shangguan F, Fei M, Wang L, Liu Y, Liu N, Lu B. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch Toxicol 2019;93:3367-83. [PMID: 31563988 DOI: 10.1007/s00204-019-02579-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
103 Amrehn M, Steidl S, Kortekaas R, Strumia M, Weingarten M, Kowarschik M, Maier A. A Semi-Automated Usability Evaluation Framework for Interactive Image Segmentation Systems. Int J Biomed Imaging 2019;2019:1464592. [PMID: 31582963 DOI: 10.1155/2019/1464592] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
104 [DOI: 10.1109/icip.2019.8803471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
105 Liu T, Wang W, Cui H, Sun M, Wang Y, Liu X, Cao L, Liu H, Liu S. Elevated fasting serum glucose levels increase the risk of hepatocellular carcinoma: A prospective cohort study. Medicine (Baltimore) 2019;98:e16369. [PMID: 31348238 DOI: 10.1097/MD.0000000000016369] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
107 Choi GH, Kim GA, Choi J, Han S, Lim YS. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [PMID: 31135074 DOI: 10.1111/apt.15311] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
108 Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life. Cancers (Basel). 2019;11. [PMID: 31216701 DOI: 10.3390/cancers11060841] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 10.8] [Reference Citation Analysis]
109 Cheng HH, Kamarck TW, Gianaros PJ, Roecklein KA, Vanegas Y, Tsung A, Geller DA, Marsh JW, Ahmed NS, Steel JL. Socioeconomic disparities of depressive symptoms and cytokines in hepatocellular carcinoma. Psychooncology 2019;28:1624-32. [PMID: 31119824 DOI: 10.1002/pon.5127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
110 Chiang CH, Kuo CS, Lin WW, Su JH, Chen JD, Huang KC. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study. Int J Environ Res Public Health 2019;16:E2097. [PMID: 31200528 DOI: 10.3390/ijerph16122097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
111 Bitterman DS, Sanford NN, Niemierko A, Mahal BA, Qadan M, Ganguli S, Blaszkowsky LS, Zhu AX, Hong TS, Devlin PM, Goyal L, Wo JY. Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. Am J Clin Oncol 2019;42:564-72. [PMID: 31166209 DOI: 10.1097/COC.0000000000000560] [Reference Citation Analysis]
112 Oura K, Fujita K, Morishita A, Iwama H, Nakahara M, Tadokoro T, Sakamoto T, Nomura T, Yoneyama H, Mimura S, Tani J, Kobara H, Okano K, Suzuki Y, Masaki T. Serum microRNA-125a-5p as a potential biomarker of HCV-associated hepatocellular carcinoma. Oncol Lett 2019;18:882-90. [PMID: 31289566 DOI: 10.3892/ol.2019.10385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
113 Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, Al-Raddadi R, Alvis-Guzman N, Amoako Y, Artaman A, Ayele TA, Barac A, Bensenor I, Berhane A, Bhutta Z, Castillo-Rivas J, Chitheer A, Choi JY, Cowie B, Dandona L, Dandona R, Dey S, Dicker D, Phuc H, Ekwueme DU, Zaki MS, Fischer F, Fürst T, Hancock J, Hay SI, Hotez P, Jee SH, Kasaeian A, Khader Y, Khang YH, Kumar A, Kutz M, Larson H, Lopez A, Lunevicius R, Malekzadeh R, McAlinden C, Meier T, Mendoza W, Mokdad A, Moradi-Lakeh M, Nagel G, Nguyen Q, Nguyen G, Ogbo F, Patton G, Pereira DM, Pourmalek F, Qorbani M, Radfar A, Roshandel G, Salomon JA, Sanabria J, Sartorius B, Satpathy M, Sawhney M, Sepanlou S, Shackelford K, Shore H, Sun J, Mengistu DT, Topór-Mądry R, Tran B, Ukwaja KN, Vlassov V, Vollset SE, Vos T, Wakayo T, Weiderpass E, Werdecker A, Yonemoto N, Younis M, Yu C, Zaidi Z, Zhu L, Murray CJL, Naghavi M, Fitzmaurice C; Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol 2017;3:1683-91. [PMID: 28983565 DOI: 10.1001/jamaoncol.2017.3055] [Cited by in Crossref: 924] [Cited by in F6Publishing: 1027] [Article Influence: 231.0] [Reference Citation Analysis]
114 Pope ED 3rd, Kimbrough EO, Vemireddy LP, Surapaneni PK, Copland JA 3rd, Mody K. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin Ther Targets 2019;23:473-83. [PMID: 31076001 DOI: 10.1080/14728222.2019.1615883] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
115 Sheng Z, Wang X, Xu G, Shan G, Chen L. Analyses of a Panel of Transcripts Identified From a Small Sample Size and Construction of RNA Networks in Hepatocellular Carcinoma. Front Genet 2019;10:431. [PMID: 31156698 DOI: 10.3389/fgene.2019.00431] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
116 Sun Y, Zhang F, Wang L, Song X, Jing J, Zhang F, Yu S, Liu H. A five lncRNA signature for prognosis prediction in hepatocellular carcinoma. Mol Med Rep 2019;19:5237-50. [PMID: 31059056 DOI: 10.3892/mmr.2019.10203] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
117 Chen CY, Wu SM, Lin YH, Chi HC, Lin SL, Yeh CT, Chuang WY, Lin KH. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer. Theranostics 2019;9:2361-79. [PMID: 31149049 DOI: 10.7150/thno.29628] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
118 Thomas AJ, Menias CO, Pickhardt PJ, Shaaban AM, Gaballah AH, Yedururi S, Elsayes KM. Bleeding Liver Masses: Imaging Features With Pathologic Correlation and Impact on Management. AJR Am J Roentgenol 2019;213:8-16. [PMID: 30973778 DOI: 10.2214/AJR.19.21240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
119 Cocker F, Chien Yee K, Palmer AJ, de Graaff B. Increasing incidence and mortality related to liver cancer in Australia: time to turn the tide. Aust N Z J Public Health 2019;43:267-73. [PMID: 30958629 DOI: 10.1111/1753-6405.12889] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
120 Buonomo AR, Scotto R, Zappulo E, Nerilli M, Pinchera B, Perruolo G, Formisano P, Nappa S, Gentile I. Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. In Vivo 2019;33:177-82. [PMID: 30587620 DOI: 10.21873/invivo.11456] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
121 Luo YY, Zhang HP, Huang AL, Hu JL. Association between KIF1B rs17401966 genetic polymorphism and hepatocellular carcinoma susceptibility: an updated meta-analysis. BMC Med Genet 2019;20:59. [PMID: 30947687 DOI: 10.1186/s12881-019-0778-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Kumar DP, Santhekadur PK, Seneshaw M, Mirshahi F, Uram-Tuculescu C, Sanyal AJ. A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Hepatology 2019;69:1520-34. [PMID: 30394550 DOI: 10.1002/hep.30346] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
123 Montoya-guzmán M, Duque-jaramillo A, Gaviria-calle M, Hoyos S, Restrepo-gutiérrez JC, Navas-navas M. Mutación R249S TP53 en pacientes con cirrosis y carcinoma hepatocelular en un hospital de Medellín. CES Med 2019;33:100-110. [DOI: 10.21615/cesmedicina.33.2.3] [Reference Citation Analysis]
124 Lai MW, Chu YD, Lin CL, Chien RN, Yeh TS, Pan TL, Ke PY, Lin KH, Yeh CT. Is there a sex difference in postoperative prognosis of hepatocellular carcinoma? BMC Cancer 2019;19:250. [PMID: 30894157 DOI: 10.1186/s12885-019-5453-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
125 Yan G, Liu Z. Identification of differentially expressed genes in hepatocellular carcinoma by integrated bioinformatic analysis.. [DOI: 10.1101/570846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 VoPham T. Environmental risk factors for liver cancer and nonalcoholic fatty liver disease. Curr Epidemiol Rep 2019;6:50-66. [PMID: 31080703 DOI: 10.1007/s40471-019-0183-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
127 Shi C, Xu H, Liu J, Zhong Y, Zhang X, Tong X, Zhang L, Li X, Deng L. Alternatively activated NUSAP1 promotes tumor growth and indicates poor prognosis in hepatocellular carcinoma. Transl Cancer Res 2019;8:238-47. [PMID: 35116752 DOI: 10.21037/tcr.2019.01.29] [Reference Citation Analysis]
128 Rizell M, Sternby Eilard M, Andersson M, Andersson B, Karlsson-Parra A, Suenaert P. Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol. 2019;9:19. [PMID: 30719425 DOI: 10.3389/fonc.2019.00019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
129 Qu C, Huang X, Liu K, Li K, Tan B, Qu L, Cao J, Zhu C. Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma. Infect Agent Cancer 2019;14:2. [PMID: 30679943 DOI: 10.1186/s13027-019-0219-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
130 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
131 Gu J, Liu X, Li J, He Y. MicroRNA-144 inhibits cell proliferation, migration and invasion in human hepatocellular carcinoma by targeting CCNB1. Cancer Cell Int 2019;19:15. [PMID: 30651720 DOI: 10.1186/s12935-019-0729-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 11.5] [Reference Citation Analysis]
132 Luo J, Chen XQ, Li P. The Role of TGF-β and Its Receptors in Gastrointestinal Cancers. Transl Oncol 2019;12:475-84. [PMID: 30594036 DOI: 10.1016/j.tranon.2018.11.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
133 Pottakkat B, Ashokachakkaravarthy K. Sorafenib resistance and autophagy in hepatocellular carcinoma: A concealed threat. J Cancer Res Pract 2019;6:107. [DOI: 10.4103/jcrp.jcrp_6_19] [Reference Citation Analysis]
134 Jindal A, Thadi A, Shailubhai K. Hepatocellular Carcinoma: Etiology and Current and Future Drugs. J Clin Exp Hepatol 2019;9:221-32. [PMID: 31024205 DOI: 10.1016/j.jceh.2019.01.004] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 28.8] [Reference Citation Analysis]
135 Engin AB, Engin A. DNA damage checkpoint response to aflatoxin B1. Environmental Toxicology and Pharmacology 2019;65:90-6. [DOI: 10.1016/j.etap.2018.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
136 Chen VC, Chan H, Hsu T, Lu M, Lee Y, Lee Y, Siow JY, Mcintyre RS, Zhou AJ, Tzang B, Lee CT. New use for old drugs: The protective effect of atypical antipsychotics on hepatocellular carcinoma. Int J Cancer 2019;144:2428-39. [DOI: 10.1002/ijc.31980] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
137 Kou P, Zhang C, Lin J, Wang H. Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma. Oncol Lett 2019;17:2091-8. [PMID: 30675276 DOI: 10.3892/ol.2018.9863] [Cited by in Crossref: 4] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
138 Khantimirova LM, Kozlova TY, Postnova EL, Shevtsov VA, Rukavishnikov AV. Retrospective Analysis of Viral Hepatitis B Incidence in Russia from 2013 to 2017 in the Context of Preventive Vaccination. Biopreparaty Profilaktika, diagnostika, lechenie 2018;18:225-235. [DOI: 10.30895/2221-996x-2018-18-4-225-235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
139 Valean S, Chira R, Dumitrascu D. Epidemiological trends in digestive cancers in Romania, 1955-2012, compared to alcohol consumption. Correlation or coincidence? Clujul Med 2018;91:376-86. [PMID: 30564012 DOI: 10.15386/cjmed-1067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
140 Pagano AP, Sicchieri JMF, Passos CR, Manca CS, Schiavoni IL, Teixeira AC, Martinelli ADLC, Chiarello PG. Hand grip strength and adductor pollicis muscle thickness in patients on palliative care for hepatocellular carcinoma. Clinical Nutrition Experimental 2018;22:30-5. [DOI: 10.1016/j.yclnex.2018.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
141 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 102] [Cited by in F6Publishing: 117] [Article Influence: 20.4] [Reference Citation Analysis]
142 Ramos-lopez O, Riezu-boj JI, Milagro FI, Alfredo Martinez J; On Behalf of the MENA Project. Association of Methylation Signatures at Hepatocellular Carcinoma Pathway Genes with Adiposity and Insulin Resistance Phenotypes. Nutrition and Cancer 2019;71:840-51. [DOI: 10.1080/01635581.2018.1531136] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
143 Ren A, Luo S, Ji L, Yi X, Liang J, Wang J, Wan S. Peritoneal metastasis after emergency hepatectomy and delayed hepatectomy for spontaneous rupture of hepatocellular carcinoma. Asian J Surg 2019;42:464-9. [PMID: 30420157 DOI: 10.1016/j.asjsur.2018.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
144 Yaprak O, Acar S, Ertugrul G, Dayangac M. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10(10): 336-343 [PMID: 30364796 DOI: 10.4251/wjgo.v10.i10.336] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
145 Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein MM, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan MY, Hampe J. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol 2018;113:1475-83. [PMID: 29535416 DOI: 10.1038/s41395-018-0041-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 11.6] [Reference Citation Analysis]
146 Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 Chaudhary K, Poirion OB, Lu L, Huang S, Ching T, Garmire LX. Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes. Clin Cancer Res 2019;25:463-72. [PMID: 30242023 DOI: 10.1158/1078-0432.CCR-18-0088] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
148 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
149 Yoshida Y, Furukawa J, Naito S, Higashino K, Numata Y, Shinohara Y. Identification of unique glycoisoforms of vitamin D-binding protein and haptoglobin as biomarker candidates in hepatocarcinogenesis of STAM mice. Glycoconj J 2018;35:467-76. [DOI: 10.1007/s10719-018-9838-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
150 Mishra M, Jayal P, Karande AA, Chandra N. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach. FEBS J 2018;285:3977-92. [PMID: 30136368 DOI: 10.1111/febs.14641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
151 Wu WD, Chen PS, Omar HA, Arafa EA, Pan HW, Jeng J, Hung JH. Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Sci Rep 2018;8:12914. [PMID: 30150684 DOI: 10.1038/s41598-018-31209-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
152 Golemis EA, Scheet P, Beck TN, Scolnick EM, Hunter DJ, Hawk E, Hopkins N. Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 2018;32:868-902. [PMID: 29945886 DOI: 10.1101/gad.314849.118] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 15.2] [Reference Citation Analysis]
153 Ahn SM, Haq F, Park I, Nault JC, Zucman-Rossi J, Yu E. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer 2018;18:571. [PMID: 29776391 DOI: 10.1186/s12885-018-4192-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
154 Han H, Zhang T, Jin Z, Guo H, Wei X, Liu Y, Chen Q, He J. Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies. Oncotarget 2017;8:50164-73. [PMID: 28432278 DOI: 10.18632/oncotarget.16816] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
155 Lai GY, Wang JB, Weinstein SJ, Parisi D, Horst RL, McGlynn KA, Männistö S, Albanes D, Freedman ND. Association of 25-Hydroxyvitamin D with Liver Cancer Incidence and Chronic Liver Disease Mortality in Finnish Male Smokers of the ATBC Study. Cancer Epidemiol Biomarkers Prev 2018;27:1075-82. [PMID: 29720370 DOI: 10.1158/1055-9965.EPI-17-0877] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
156 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 2018;67:945-52. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 24.0] [Reference Citation Analysis]
157 Hwang IC, Chang J, Kim K, Park SM. Aspirin Use and Risk of Hepatocellular Carcinoma in a National Cohort Study of Korean Adults. Sci Rep 2018;8:4968. [PMID: 29563592 DOI: 10.1038/s41598-018-23343-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
158 Petrick JL, Campbell PT, Koshiol J, Thistle JE, Andreotti G, Beane-Freeman LE, Buring JE, Chan AT, Chong DQ, Doody MM. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: The Liver Cancer Pooling Project. Br J Cancer. 2018;118:1005-1012. [PMID: 29520041 DOI: 10.1038/s41416-018-0007-z] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
159 Chen VC, Lin CF, Hsieh YH, Liang HY, Huang KY, Chiu WC, Lee Y, McIntyre RS, Chan HL. Hepatocellular carcinoma and antidepressants: a nationwide population-based study. Oncotarget 2017;8:30464-70. [PMID: 27783998 DOI: 10.18632/oncotarget.12826] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
160 Yan L, Jakate S, Reddy V, Gattuso P. Metastatic hepatocellular carcinoma diagnosed by fine needle aspiration: A clinical and cytologic study. Diagn Cytopathol 2018;46:495-500. [PMID: 29493103 DOI: 10.1002/dc.23920] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
161 Fernández-Vega I, Santos-Juanes J, Camacho-Urkaray E, Lorente-Gea L, García B, Gutiérrez-Corres FB, Quirós LM, Guerra-Merino I, Aguirre JJ. Miki (Mitotic Kinetics Regulator) Immunoexpression in Normal Liver, Cirrhotic Areas and Hepatocellular Carcinomas: a Preliminary Study with Clinical Relevance. Pathol Oncol Res 2020;26:167-73. [PMID: 29435733 DOI: 10.1007/s12253-018-0387-7] [Reference Citation Analysis]
162 Yartel AK, Rein DB, Brown KA, Krauskopf K, Massoud OI, Jordan C, Kil N, Federman AD, Nerenz DR, Brady JE, Kruger DL, Smith BD. Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials. Hepatology 2018;67:524-33. [PMID: 28941361 DOI: 10.1002/hep.29548] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
163 Suh CH, Kim KW, Park SH, Kim SY, Woo D, Shin S, Pyo J, Shinagare AB, Ramaiya NH, Lim Y. Performing Gadoxetic Acid–Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. American Journal of Roentgenology 2018;210:W63-9. [DOI: 10.2214/ajr.17.18300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
164 Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67:600-11. [PMID: 28859220 DOI: 10.1002/hep.29498] [Cited by in Crossref: 140] [Cited by in F6Publishing: 148] [Article Influence: 28.0] [Reference Citation Analysis]
165 Yilmaz Y, Colak Y, Kurt R, Senates E, Eren F. Linking Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: From Bedside to Bench and Back. Tumori 2013;99:10-6. [DOI: 10.1177/030089161309900102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
166 Elsayed AG, Martin JM, Pacioles T. Rash and subcutaneous fat necrosis after DEB-TACE with doxorubicin. BMJ Case Rep 2018;2018:bcr-2017-222394. [PMID: 29305365 DOI: 10.1136/bcr-2017-222394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
167 Bhaskar LVKS, Saikrishna L. Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. Role of Tyrosine Kinases in Gastrointestinal Malignancies 2018. [DOI: 10.1007/978-981-13-1486-5_14] [Reference Citation Analysis]
168 Ye JZ, Yan SM, Yuan CL, Wu HN, Zhang JY, Liu ZH, Li YQ, Luo XL, Lin Y, Liang R. GP73 level determines chemotherapeutic resistance in human hepatocellular carcinoma cells. J Cancer 2018;9:415-23. [PMID: 29344288 DOI: 10.7150/jca.19185] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
169 Ko KP, Shin A, Cho S, Park SK, Yoo KY. Environmental contributions to gastrointestinal and liver cancer in the Asia-Pacific region. J Gastroenterol Hepatol 2018;33:111-20. [PMID: 28960448 DOI: 10.1111/jgh.14005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
170 Esposti DD, Hernandez-Vargas H, Voegele C, Fernandez-Jimenez N, Forey N, Bancel B, Le Calvez-Kelm F, McKay J, Merle P, Herceg Z. Identification of novel long non-coding RNAs deregulated in hepatocellular carcinoma using RNA-sequencing. Oncotarget. 2016;7:31862-31877. [PMID: 26887054 DOI: 10.18632/oncotarget.7364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
171 Taddei TH, Lo Re V 3rd, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Curr HIV/AIDS Rep 2016;13:269-78. [PMID: 27614654 DOI: 10.1007/s11904-016-0327-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
172 Kang D, Han Z, Oh GH, Joo Y, Choi HJ, Song JJ. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Med J 2017;58:899-909. [PMID: 28792132 DOI: 10.3349/ymj.2017.58.5.899] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
173 Editorial Office of Chinese Journal of Cancer. The 150 most important questions in cancer research and clinical oncology series: questions 76-85 : Edited by Chinese Journal of Cancer. Chin J Cancer 2017;36:91. [PMID: 29151366 DOI: 10.1186/s40880-017-0259-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
174 Mehra M, Chauhan R. Long Noncoding RNAs as a Key Player in Hepatocellular Carcinoma. Biomark Cancer 2017;9:1179299X17737301. [PMID: 29147078 DOI: 10.1177/1179299X17737301] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
175 He Q, Wang F, Honda T, Lindquist DM, Dillman JR, Timchenko NA, Redington AN. Intravenous miR-144 inhibits tumor growth in diethylnitrosamine-induced hepatocellular carcinoma in mice. Tumour Biol 2017;39:1010428317737729. [PMID: 29072132 DOI: 10.1177/1010428317737729] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
176 Kim GA, Han S, Kim HD, An J, Lim YS. Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. J Viral Hepat 2017;24:990-7. [PMID: 28499070 DOI: 10.1111/jvh.12723] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
177 Peloso A, Oldani G. Enlarged selection criteria for hepatocellular cancer: is the upper limit needed? Transl Gastroenterol Hepatol 2017;2:73. [PMID: 29034346 DOI: 10.21037/tgh.2017.09.02] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Wang L, Li Y, Xu J, Zhang A, Wang X, Tang R, Zhang X, Yin H, Liu M, Wang DD, Lin PP, Shen L, Dong J. Quantified postsurgical small cell size CTCs and EpCAM+ circulating tumor stem cells with cytogenetic abnormalities in hepatocellular carcinoma patients determine cancer relapse. Cancer Lett 2018;412:99-107. [PMID: 29031565 DOI: 10.1016/j.canlet.2017.10.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
179 Kim HJ, Jeong J, Park S, Jin YW, Lee SS, Lee SB, Choi D. Establishment of Hepatocellular Cancer Induced Pluripotent Stem Cells Using a Reprogramming Technique. Gut Liver 2017;11:261-9. [PMID: 27728962 DOI: 10.5009/gnl15389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
180 Atiya A, Sinha BN, Ranjan Lal U. New chemical constituents from the Piper betle Linn. (Piperaceae). Natural Product Research 2018;32:1080-7. [DOI: 10.1080/14786419.2017.1380018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
181 Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 2017;8:799-807. [PMID: 29184683 DOI: 10.21037/jgo.2017.08.03] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
182 Weng MW, Lee HW, Choi B, Wang HT, Hu Y, Mehta M, Desai D, Amin S, Zheng Y, Tang MS. AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249. Oncotarget 2017;8:18213-26. [PMID: 28212554 DOI: 10.18632/oncotarget.15313] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
183 Zheng J, Chou JF, Gönen M, Vachharajani N, Chapman WC, Majella Doyle MB, Turcotte S, Vandenbroucke-Menu F, Lapointe R, Buettner S, Groot Koerkamp B, Ijzermans JNM, Chan CY, Goh BKP, Teo JY, Kam JH, Jeyaraj PR, Cheow PC, Chung AYF, Chow PKH, Ooi LLPJ, Balachandran VP, Kingham TP, Allen PJ, D'Angelica MI, DeMatteo RP, Jarnagin WR, Lee SY. Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort. Ann Surg 2017;266:693-701. [PMID: 28650354 DOI: 10.1097/SLA.0000000000002360] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
184 Li G, Zhang W, Gong L, Huang X. MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3. Oncol Res 2019;27:449-58. [PMID: 28800792 DOI: 10.3727/096504017X15016337254623] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
185 Thillai K, Srikandarajah K, Ross P. Regorafenib as treatment for patients with advanced hepatocellular cancer. Future Oncol. 2017;13:2223-2232. [PMID: 28766967 DOI: 10.2217/fon-2017-0204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
186 Hamaoka M, Kobayashi T, Kuroda S, Iwako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayama K, Ohdan H. Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. International Journal of Surgery 2017;44:223-8. [DOI: 10.1016/j.ijsu.2017.06.082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
187 Pham HHT, Seong Y, Ngabire D, Oh C, Kim G. Cyperus amuricus induces G1 arrest and apoptosis through endoplasmic reticulum stress and mitochondrial signaling in human hepatocellular carcinoma Hep3B cells. Journal of Ethnopharmacology 2017;208:157-64. [DOI: 10.1016/j.jep.2017.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
188 Uygun A. Is That Possible to Stop or Cease the NASH to Turn into HCC? J Gastrointest Cancer 2017;48:250-5. [PMID: 28733789 DOI: 10.1007/s12029-017-9961-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
189 Chaudhary K, Poirion OB, Lu L, Huang S, Ching T, Garmire LX. Multi-modal meta-analysis of 1494 hepatocellular carcinoma samples reveals vast impacts of consensus driver genes on phenotypes.. [DOI: 10.1101/166090] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
190 Li J, Liu W, Zhu W, Wu Y, Wu B. Transcatheter hepatic arterial chemoembolization and sorafenib for hepatocellular carcinoma: a meta-analysis of randomized, double-blind controlled trials. Oncotarget. 2017;8:59601-59608. [PMID: 28938663 DOI: 10.18632/oncotarget.19334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
191 Liu P, Xie SH, Hu S, Cheng X, Gao T, Zhang C, Song Z. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget 2017;8:68131-7. [PMID: 28978103 DOI: 10.18632/oncotarget.19245] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 7.3] [Reference Citation Analysis]
192 Kasai Y, Hatano E, Seo S, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy. Surgery. 2017;162:742-751. [PMID: 28705491 DOI: 10.1016/j.surg.2017.05.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
193 Liou AT, Chen MF, Yang CW. Curcumin Induces p53-Null Hepatoma Cell Line Hep3B Apoptosis through the AKT-PTEN-FOXO4 Pathway. Evid Based Complement Alternat Med 2017;2017:4063865. [PMID: 28769986 DOI: 10.1155/2017/4063865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
194 Lv J, Xu T, Qian Z, Wang H. Association between HLA-DQ Gene Polymorphisms and HBV-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2017;2017:7150386. [PMID: 28761441 DOI: 10.1155/2017/7150386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
195 Mantovani A, Targher G. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med. 2017;5:270. [PMID: 28758096 DOI: 10.21037/atm.2017.04.41] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 10.8] [Reference Citation Analysis]
196 Lee J, Lee JH, Yoon H, Lee HJ, Jeon H, Nam J. Extraordinary radiation super-sensitivity accompanying with sorafenib combination therapy: what lies beneath? Radiat Oncol J 2017;35:185-8. [PMID: 28712281 DOI: 10.3857/roj.2017.00262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
197 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 986] [Cited by in F6Publishing: 915] [Article Influence: 164.3] [Reference Citation Analysis]
198 Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE; VOCAL Study Group. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017;152:1954-64. [PMID: 28283421 DOI: 10.1053/j.gastro.2017.02.040] [Cited by in Crossref: 134] [Cited by in F6Publishing: 135] [Article Influence: 22.3] [Reference Citation Analysis]
199 Zhong D, Cen H. Aberrant promoter methylation profiles and association with survival in patients with hepatocellular carcinoma. Onco Targets Ther 2017;10:2501-9. [PMID: 28507442 DOI: 10.2147/OTT.S128058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
200 Wei X, Li N, Li S, Shi J, Guo W, Zheng Y, Cheng S. Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma. BMC Cancer 2017;17:304. [PMID: 28464845 DOI: 10.1186/s12885-017-3293-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
201 Amer T, El-baz R, Mokhtar A, El-shaer S, Elshazli R, Settin A. Genetic polymorphisms of IL-23R (rs7517847) and LEP (rs7799039) among Egyptian patients with hepatocellular carcinoma. Archives of Physiology and Biochemistry 2017;123:279-85. [DOI: 10.1080/13813455.2017.1320680] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
202 Loosen SH, Schueller F, Trautwein C, Roy S, Roderburg C. Role of circulating microRNAs in liver diseases. World J Hepatol 2017; 9(12): 586-594 [PMID: 28515844 DOI: 10.4254/wjh.v9.i12.586] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
203 Fasullo M, Freedland J, St John N, Cera C, Egner P, Hartog M, Ding X. An in vitro system for measuring genotoxicity mediated by human CYP3A4 in Saccharomyces cerevisiae. Environ Mol Mutagen 2017;58:217-27. [PMID: 28436563 DOI: 10.1002/em.22093] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
204 Kasai Y, Toriguchi K, Hatano E, Nishi K, Ohno M, Yoh T, Fukuyama K, Nishio T, Okuno M, Iwaisako K, Seo S, Taura K, Kurokawa M, Kunichika M, Uemoto S, Nishi E. Nardilysin promotes hepatocellular carcinoma through activation of signal transducer and activator of transcription 3. Cancer Sci 2017;108:910-7. [PMID: 28207963 DOI: 10.1111/cas.13204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
205 Fedirko V, Tran HQ, Gewirtz AT, Stepien M, Trichopoulou A, Aleksandrova K, Olsen A, Tjønneland A, Overvad K, Carbonnel F, Boutron-Ruault MC, Severi G, Kühn T, Kaaks R, Boeing H, Bamia C, Lagiou P, Grioni S, Panico S, Palli D, Tumino R, Naccarati A, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Castaño JM, Barricarte A, Sánchez MJ, Dorronsoro M, Quirós JR, Agudo A, Sjöberg K, Ohlsson B, Hemmingsson O, Werner M, Bradbury KE, Khaw KT, Wareham N, Tsilidis KK, Aune D, Scalbert A, Romieu I, Riboli E, Jenab M. Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. BMC Med 2017;15:72. [PMID: 28372583 DOI: 10.1186/s12916-017-0830-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
206 Tunissiolli NM, Castanhole-Nunes MMU, Biselli-Chicote PM, Pavarino EC, da Silva RF, da Silva RC, Goloni-Bertollo EM. Hepatocellular Carcinoma: a Comprehensive Review of Biomarkers, Clinical Aspects, and Therapy. Asian Pac J Cancer Prev. 2017;18:863-872. [PMID: 28545181 DOI: 10.22034/apjcp.2017.18.4.863] [Cited by in F6Publishing: 40] [Reference Citation Analysis]
207 Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017;96:e5904. [PMID: 28248853 DOI: 10.1097/md.0000000000005904] [Cited by in Crossref: 113] [Cited by in F6Publishing: 126] [Article Influence: 18.8] [Reference Citation Analysis]
208 Zarrinpar A. Metabolic Pathway Inhibition in Liver Cancer. SLAS Technol 2017;22:237-44. [PMID: 28314110 DOI: 10.1177/2472630317698683] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
209 Feng S, Han M, Zhou L, Wang Q, Li Z, Li Y, Lu H, Liu T, Ma Y, Liu S, Cheng J. NS5ABP37 inhibits liver cancer by impeding lipogenesis and cholesterogenesis. Cancer Sci 2017;108:12-22. [PMID: 27862769 DOI: 10.1111/cas.13117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
210 Delfine V, Bernasconi E, Bardelli D, Spataro V, Fusi-Schmidhauser T. Intractable Neck Pain in an Oncologic Palliative Care Setting: Is Cancer Always the Answer? J Pain Palliat Care Pharmacother 2017;31:43-4. [PMID: 28287358 DOI: 10.1080/15360288.2017.1279503] [Reference Citation Analysis]
211 Ferlay J, Wild CP, Bray F. The Burden of Cancer Worldwide: Current and Future Perspectives. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
212 Liu X, Liu F, Gao S, Reske J, Li A, Wu CL, Yang C, Chen F, Luo R, Xiao H. A single non-synonymous NCOA5 variation in type 2 diabetic patients with hepatocellular carcinoma impairs the function of NCOA5 in cell cycle regulation. Cancer Lett 2017;391:152-61. [PMID: 28137631 DOI: 10.1016/j.canlet.2017.01.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
213 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017;4:15-21. [PMID: 28144610 DOI: 10.2147/JHC.S94008] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
214 Muriel P. The Liver. Liver Pathophysiology. Elsevier; 2017. pp. 3-22. [DOI: 10.1016/b978-0-12-804274-8.00001-1] [Cited by in Crossref: 12] [Article Influence: 2.0] [Reference Citation Analysis]
215 Buivydiene A, Liakina V, Valantinas J, Norkuniene J, Mockiene E, Jokubauskiene S, Smaliukiene R, Jancoriene L, Kovalevska L, Kashuba E. Expression Levels of the Uridine-Cytidine Kinase Like-1 Protein As a Novel Prognostic Factor for Hepatitis C Virus-Associated Hepatocellular Carcinomas. Acta Naturae 2017;9:108-14. [PMID: 29104783] [Reference Citation Analysis]
216 Coleman WB, Tsongalis GJ. Cancer Epidemiology: Incidence and Etiology of Human Neoplasms. The Molecular Basis of Human Cancer 2017. [DOI: 10.1007/978-1-59745-458-2_1] [Reference Citation Analysis]
217 Zimmermann A. Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 2017. [DOI: 10.1007/978-3-319-26956-6_2] [Reference Citation Analysis]
218 Soares do Amaral N, Cruz E Melo N, de Melo Maia B, Malagoli Rocha R. Noncoding RNA Profiles in Tobacco- and Alcohol-Associated Diseases. Genes (Basel) 2016;8:E6. [PMID: 28025544 DOI: 10.3390/genes8010006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
219 Yang B, Shebl FM, Sternberg LR, Warner AC, Kleiner DE, Edelman DC, Gomez A, Dagnall CL, Hicks BD, Altekruse SF, Hernandez BY, Lynch CF, Meltzer PS, McGlynn KA. Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States. PLoS One 2016;11:e0166828. [PMID: 27880792 DOI: 10.1371/journal.pone.0166828] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
220 Lin YC, Owen N, Minko IG, Lange SS, Tomida J, Li L, Stone MP, Wood RD, McCullough AK, Lloyd RS. DNA polymerase ζ limits chromosomal damage and promotes cell survival following aflatoxin exposure. Proc Natl Acad Sci U S A 2016;113:13774-9. [PMID: 27849610 DOI: 10.1073/pnas.1609024113] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
221 Cullen JM. Tumors of the Liver and Gallbladder. Tumors in Domestic Animals 2016. [DOI: 10.1002/9781119181200.ch14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
222 Yang B, Yang HP, Ward KK, Sahasrabuddhe VV, McGlynn KA. Bariatric Surgery and Liver Cancer in a Consortium of Academic Medical Centers. Obes Surg 2016;26:696-700. [PMID: 26757918 DOI: 10.1007/s11695-016-2051-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
223 Zhong GC, Liu Y, Chen N, Hao FB, Wang K, Cheng JH, Gong JP, Ding X. Reproductive factors, menopausal hormone therapies and primary liver cancer risk: a systematic review and dose-response meta-analysis of observational studies. Hum Reprod Update 2016;23:126-38. [PMID: 27655589 DOI: 10.1093/humupd/dmw037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
224 Cao Y, Chen J, Wang D, Peng H, Tan X, Xiong D, Huang A, Tang H. Upregulated in Hepatitis B virus-associated hepatocellular carcinoma cells, miR-331-3p promotes proliferation of hepatocellular carcinoma cells by targeting ING5. Oncotarget. 2015;6:38093-38106. [PMID: 26497554 DOI: 10.18632/oncotarget.5642] [Cited by in Crossref: 41] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
225 Guo J, Turesky RJ. Human Biomonitoring of DNA Adducts by Ion Trap Multistage Mass Spectrometry. Curr Protoc Nucleic Acid Chem 2016;66:7.24.1-7.24.25. [PMID: 27584705 DOI: 10.1002/cpnc.12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
226 Loftfield E, Freedman ND, Lai GY, Weinstein SJ, McGlynn KA, Taylor PR, Männistö S, Albanes D, Stolzenberg-Solomon RZ. Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. Cancer Prev Res (Phila) 2016;9:866-74. [PMID: 27574287 DOI: 10.1158/1940-6207.CAPR-16-0141] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
227 Su C, Lin Y, Cai L, Mao Q, Niu J. Association between mannose-binding lectin variants, haplotypes and risk of hepatocellular carcinoma: A case-control study. Sci Rep 2016;6:32147. [PMID: 27557564 DOI: 10.1038/srep32147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
228 Lee PC, Yeh CM, Hu YW, Chen CC, Liu CJ, Su CW, Huo TI, Huang YH, Chao Y, Chen TJ, Lin HC, Wu JC. Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. Ann Surg Oncol 2016;23:874-83. [PMID: 27541812 DOI: 10.1245/s10434-016-5520-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
229 Chiappini F, Desterke C, Bertrand-Michel J, Guettier C, Le Naour F. Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. Sci Rep 2016;6:31587. [PMID: 27510159 DOI: 10.1038/srep31587] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
230 Yim WW, Denman T, Kwan SW, Yetisgen M. Tumor information extraction in radiology reports for hepatocellular carcinoma patients. AMIA Jt Summits Transl Sci Proc 2016;2016:455-64. [PMID: 27570686] [Reference Citation Analysis]
231 Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139:1534-1545. [PMID: 27244487 DOI: 10.1002/ijc.30211] [Cited by in Crossref: 201] [Cited by in F6Publishing: 222] [Article Influence: 28.7] [Reference Citation Analysis]
232 Li N, Feng S, Xue J, Wei XB, Shi J, Guo WX, Lau WY, Wu MC, Cheng SQ, Meng Y. Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford) 2016;18:549-56. [PMID: 27317960 DOI: 10.1016/j.hpb.2016.04.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
233 Bai K, Cao Y, Huang C, Chen J, Zhang X, Jiang Y. Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months. Medicine (Baltimore) 2016;95:e2493. [PMID: 26765460 DOI: 10.1097/MD.0000000000002493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
234 Lu Q, Chen L, Zeng J, Huang G, Qin C, Cheng D, Yu L, Liang Z. Clinical Features of Liver Cancer with Cerebral Hemorrhage. Med Sci Monit 2016;22:1716-23. [PMID: 27209058 DOI: 10.12659/msm.898642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
235 Gao X, Liu W, Zhang X, Tang L, Wang L, Yan L, Yang H, Li T, Yang L, Ma N, Liu D. Genetic polymorphism of HLA-DQ confers susceptibility to hepatitis B virus-related hepatocellular carcinoma: a case-control study in Han population in China. Tumour Biol 2016;37:12103-11. [PMID: 27209411 DOI: 10.1007/s13277-016-5077-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
236 Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM, Anderson RN, Ma J, Ly KN, Cronin KA, Penberthy L, Kohler BA. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312-1337. [PMID: 26959385 DOI: 10.1002/cncr.29936] [Cited by in Crossref: 594] [Cited by in F6Publishing: 673] [Article Influence: 84.9] [Reference Citation Analysis]
237 Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon 2016;16:e35106. [PMID: 27226803 DOI: 10.5812/hepatmon.35106] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
238 Wei XB, Xu J, Li N, Yu Y, Shi J, Guo WX, Cheng HY, Wu MC, Lau WY, Cheng SQ. The role of three-dimensional imaging in optimizing diagnosis, classification and surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. HPB (Oxford) 2016;18:287-95. [PMID: 27017169 DOI: 10.1016/j.hpb.2015.10.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
239 An N. Oral Contraceptives Use and Liver Cancer Risk: A Dose-Response Meta-Analysis of Observational Studies. Medicine (Baltimore) 2015;94:e1619. [PMID: 26512555 DOI: 10.1097/MD.0000000000001619] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
240 Hagberg KW, Sahasrabuddhe VV, McGlynn KA, Jick SS. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink. Pharmacotherapy 2016;36:187-95. [PMID: 26846893 DOI: 10.1002/phar.1704] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
241 Hafeez Bhatti AB, Dar FS, Waheed A, Shafique K, Sultan F, Shah NH. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterol Res Pract 2016;2016:5942306. [PMID: 26955390 DOI: 10.1155/2016/5942306] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
242 Setiawan VW, Lim U, Lipworth L, Lu SC, Shepherd J, Ernst T, Wilkens LR, Henderson BE, Le Marchand L. Sex and Ethnic Differences in the Association of Obesity With Risk of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2016;14:309-16. [PMID: 26404865 DOI: 10.1016/j.cgh.2015.09.015] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
243 Choi JW, Kim JH, Kim HC, Choi WS, Baek SY, Lee K, Chung JW. Comparison of tumor vascularity and hemodynamics in three rat hepatoma models. Abdom Radiol (NY) 2016;41:257-64. [PMID: 26867907 DOI: 10.1007/s00261-015-0591-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
244 Zimmermann A. Hepatocellular Carcinoma (Ordinary Hepatocellular Carcinoma). Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 2016. [DOI: 10.1007/978-3-319-26587-2_2-1] [Reference Citation Analysis]
245 Van Ha TG. Which Is Better Local Therapy for HCC, RFA or TACE? Difficult Decisions in Surgery: An Evidence-Based Approach 2016. [DOI: 10.1007/978-3-319-27365-5_12] [Reference Citation Analysis]
246 Ahn DG, Kim HJ, Kang H, Lee HW, Bae SH, Lee JH, Paik YH, Lee JS. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med 2016;31:46-53. [PMID: 26767857 DOI: 10.3904/kjim.2016.31.1.46] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
247 Zhou RR, Kuang XY, Huang Y, Li N, Zou MX, Tang DL, Fan XG. Potential role of High mobility group box 1 in hepatocellular carcinoma. Cell Adh Migr 2014;8:493-8. [PMID: 25482616 DOI: 10.4161/19336918.2014.969139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
248 Koduru P, Suzuki R, Lakhtakia S, Ramchandani M, Makmun D, Bhutani MS. Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma.J Hepatocell Carcinoma. 2015;2:143-149. [PMID: 27508203 DOI: 10.2147/JHC.S60868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
249 Faltermeier C, Busuttil RW, Zarrinpar A. A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases 2015;3:221-52. [PMID: 28943622 DOI: 10.3390/diseases3040221] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
250 Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ, Freedman ND, Fuchs CS, Gaziano JM, Giovannucci E, Graubard BI, Hollenbeck AR, Hou L, Jacobs EJ, King LY, Koshiol J, Lee IM, Linet MS, Palmer JR, Purdue MP, Rosenberg L, Schairer C, Sesso HD, Sigurdson AJ, Wactawski-Wende J, Zeleniuch-Jacquotte A, Campbell PT, McGlynn KA. NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. Cancer Prev Res (Phila) 2015;8:1156-62. [PMID: 26391917 DOI: 10.1158/1940-6207.CAPR-15-0126] [Cited by in Crossref: 56] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
251 do Nascimento JH, Soder RB, Epifanio M, Baldisserotto M. Accuracy of computer-aided ultrasound as compared with magnetic resonance imaging in the evaluation of nonalcoholic fatty liver disease in obese and eutrophic adolescents. Radiol Bras 2015;48:225-32. [PMID: 26379321 DOI: 10.1590/0100-3984.2014.0074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
252 Kitajima T, Hatano E, Mitsunori Y, Taura K, Fujimoto Y, Mizumoto M, Okajima H, Kaido T, Minamiguchi S, Uemoto S. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection. Clin J Gastroenterol. 2015;8:300-305. [PMID: 26249525 DOI: 10.1007/s12328-015-0594-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
253 Valero V 3rd, Pawlik TM, Anders RA. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:69-78. [PMID: 27508196 DOI: 10.2147/JHC.S48505] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
254 Kim HD, Lim YS, Han S, An J, Kim GA, Kim SY, Lee SJ, Won HJ, Byun JH. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology 2015;148:1371-82. [PMID: 25733098 DOI: 10.1053/j.gastro.2015.02.051] [Cited by in Crossref: 85] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
255 Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, Buonaguro L. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. Cancer Immunol Immunother 2015;64:1305-14. [DOI: 10.1007/s00262-015-1698-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
256 Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, Lee D, Shim JH, Kim KM, Lim YS. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 2015;62:1092-9. [PMID: 25445399 DOI: 10.1016/j.jhep.2014.11.031] [Cited by in Crossref: 88] [Cited by in F6Publishing: 87] [Article Influence: 11.0] [Reference Citation Analysis]
257 Govaere O, Roskams T. Pathogenesis and prognosis of hepatocellular carcinoma at the cellular and molecular levels. Clin Liver Dis 2015;19:261-76. [PMID: 25921662 DOI: 10.1016/j.cld.2015.01.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
258 Tosti M, Longhi S, de Waure C, Mele A, Franco E, Ricciardi W, Filia A. Assessment of timeliness, representativeness and quality of data reported to Italy's national integrated surveillance system for acute viral hepatitis (SEIEVA). Public Health 2015;129:561-8. [DOI: 10.1016/j.puhe.2015.02.015] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
259 Dong H, Zhang L, Qian Z, Zhu X, Zhu G, Chen Y, Xie X, Ye Q, Zang J, Ren Z, Ji Q. Identification of HBV-MLL4 Integration and Its Molecular Basis in Chinese Hepatocellular Carcinoma. PLoS One. 2015;10:e0123175. [PMID: 25901726 DOI: 10.1371/journal.pone.0123175] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
260 Yartel AK, Morgan RL, Rein DB, Ann Brown K, Kil NB, Massoud OI, Fallon MB, Smith BD. HIV Infection Status as a Predictor of Hepatitis C Virus RNA Testing in Primary Care. Am J Prev Med 2015;49:423-7. [PMID: 25896194 DOI: 10.1016/j.amepre.2015.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
261 Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10. [PMID: 25892859 DOI: 10.3748/wjg.v21.i14.4103] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 114] [Article Influence: 13.3] [Reference Citation Analysis]
262 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 230] [Cited by in F6Publishing: 252] [Article Influence: 28.8] [Reference Citation Analysis]
263 McGlynn KA, Sahasrabuddhe VV, Campbell PT, Graubard BI, Chen J, Schwartz LM, Petrick JL, Alavanja MC, Andreotti G, Boggs DA. Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project. Br J Cancer. 2015;112:1266-1272. [PMID: 25742475 DOI: 10.1038/bjc.2015.58] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
264 Roumanis PS, Bhargava P, Kimia Aubin G, Choi JI, Demirjian AN, Thayer DA, Lall C. Atypical magnetic resonance imaging findings in hepatocellular carcinoma. Curr Probl Diagn Radiol 2015;44:237-45. [PMID: 25823550 DOI: 10.1067/j.cpradiol.2014.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
265 Huang W, Gao F, Li K, Wang W, Lai YR, Tang SH, Yang DH. Decaprenyl diphosphate synthase subunit 2 as a prognosis factor in hepatocellular carcinoma. World J Gastroenterol 2015; 21(10): 3055-3065 [PMID: 25780306 DOI: 10.3748/wjg.v21.i10.3055] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
266 McGlynn KA, Hagberg K, Chen J, Graubard BI, London WT, Jick S, Sahasrabuddhe VV. Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink. J Natl Cancer Inst. 2015;107. [PMID: 25722350 DOI: 10.1093/jnci/djv009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 6.0] [Reference Citation Analysis]
267 Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health 2015;15:151. [PMID: 25886390 DOI: 10.1186/s12889-015-1476-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
268 Chen W, Liu Y, Li M, Mao J, Zhang L, Huang R, Jin X, Ye L. Anti-tumor effect of α-pinene on human hepatoma cell lines through inducing G2/M cell cycle arrest. J Pharmacol Sci 2015;127:332-8. [PMID: 25837931 DOI: 10.1016/j.jphs.2015.01.008] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 12.1] [Reference Citation Analysis]
269 Palmieri VO, Santovito D, Marano G, Minerva F, Ricci L, D'Alitto F, Angelelli G, Palasciano G. Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. Radiol Med 2015;120:627-33. [PMID: 25599661 DOI: 10.1007/s11547-014-0494-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
270 Chen L, Zhang L, Liang M, Bao J, Zhang J, Xia Y, Huang X, Wang J. Magnetic resonance imaging with gadoxetic acid disodium for the detection of hepatocellular carcinoma: a meta-analysis of 18 studies. Acad Radiol 2014;21:1603-13. [PMID: 25262955 DOI: 10.1016/j.acra.2014.08.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
271 Schottenfeld D, Beebe-Dimmer J. The cancer burden attributable to biologic agents. Ann Epidemiol 2015;25:183-7. [PMID: 25523895 DOI: 10.1016/j.annepidem.2014.11.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
272 Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54. [PMID: 25153274 DOI: 10.1148/radiol.14132361] [Cited by in Crossref: 301] [Cited by in F6Publishing: 308] [Article Influence: 33.4] [Reference Citation Analysis]
273 Wong LL, Ogihara M, Ji J, Tsai N. The changing characteristics of hepatocellular cancer in Hawaii over time. Am J Surg 2015;210:146-52. [PMID: 25510478 DOI: 10.1016/j.amjsurg.2014.06.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
274 Montrose K, Krissansen GW. Design of a PROTAC that antagonizes and destroys the cancer-forming X-protein of the hepatitis B virus. Biochem Biophys Res Commun 2014;453:735-40. [PMID: 25305486 DOI: 10.1016/j.bbrc.2014.10.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
275 Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1-17. [PMID: 25444466 DOI: 10.1016/j.soc.2014.09.001] [Cited by in Crossref: 194] [Cited by in F6Publishing: 219] [Article Influence: 21.6] [Reference Citation Analysis]
276 Yin H, Peng X, Ren P, Cheng B, Li S, Qin C. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepatocellular carcinoma: a meta-analysis. Tumour Biol 2014;35:12317-26. [PMID: 25204672 DOI: 10.1007/s13277-014-2544-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
277 McGlynn KA, Divine GW, Sahasrabuddhe VV, Engel LS, VanSlooten A, Wells K, Yood MU, Alford SH. Statin use and risk of hepatocellular carcinoma in a U.S. population. Cancer Epidemiol. 2014;38:523-527. [PMID: 25113938 DOI: 10.1016/j.canep.2014.06.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
278 Hagberg KW, McGlynn KA, Sahasrabuddhe VV, Jick S. Anti-diabetic medications and risk of primary liver cancer in persons with type II diabetes. Br J Cancer 2014;111:1710-7. [PMID: 25093492 DOI: 10.1038/bjc.2014.447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
279 Li WQ, Park Y, McGlynn KA, Hollenbeck AR, Taylor PR, Goldstein AM, Freedman ND. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology 2014;60:588-97. [PMID: 24715615 DOI: 10.1002/hep.27160] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
280 Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol 2014; 20(28): 9217-9228 [PMID: 25071314 DOI: 10.3748/wjg.v20.i28.9217] [Cited by in F6Publishing: 36] [Reference Citation Analysis]
281 Li J, Huang L, Liu CF, Cao J, Yan JJ, Xu F, Wu MC, Yan YQ. Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma: A case-control study. World J Gastroenterol 2014; 20(27): 9121-9127 [PMID: 25083085 DOI: 10.3748/wjg.v20.i27.9121] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
282 Liu CY, Feng GS. NCOA5, a molecular link between type 2 diabetes and liver cancer. Hepatobiliary Surg Nutr 2014;3:106-8. [PMID: 25019069 DOI: 10.3978/j.issn.2304-3881.2014.04.02] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
283 Lim YS, Han S, Heo NY, Shim JH, Lee HC, Suh DJ. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Gastroenterology 2014;147:152-61. [PMID: 24583062 DOI: 10.1053/j.gastro.2014.02.033] [Cited by in Crossref: 112] [Cited by in F6Publishing: 115] [Article Influence: 12.4] [Reference Citation Analysis]
284 Yang H, Chen K, Wei Y, Liu F, Li H, Zhou Z, Li B. Treatment of spontaneous ruptured hepatocellular carcinoma: A single-center study. Pak J Med Sci 2014;30:472-6. [PMID: 24948961 DOI: 10.12669/pjms.303.4001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 0.3] [Reference Citation Analysis]
285 Hou W, Liu J, Chen P, Wang H, Ye BC, Qiang F. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma. Oncol Lett 2014;8:1249-54. [PMID: 25120700 DOI: 10.3892/ol.2014.2253] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
286 Lin YC, Li L, Makarova AV, Burgers PM, Stone MP, Lloyd RS. Error-prone replication bypass of the primary aflatoxin B1 DNA adduct, AFB1-N7-Gua. J Biol Chem 2014;289:18497-506. [PMID: 24838242 DOI: 10.1074/jbc.M114.561563] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
287 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
288 Wang W, Liu G, Chen L, Wang Z, Zhou L, Lu M, Xie X, Huang Y, Li W. Preliminary experience of a new perspective view technology for the detection of portal vein thrombus in hepatocellular carcinoma patients. Abdom Imaging 2014;39:1145-52. [DOI: 10.1007/s00261-014-0145-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
289 Furtado R, Crawford M, Sandroussi C. Systematic Review and Meta-Analysis of Adjuvant I131 Lipiodol after Excision of Hepatocellular Carcinoma. Ann Surg Oncol 2014;21:2700-7. [DOI: 10.1245/s10434-014-3511-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
290 Guo J, Ma Z, Ma Q, Wu Z, Fan P, Zhou X, Chen L, Zhou S, Goltzman D, Miao D, Wu E. 1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes. Curr Med Chem 2013;20:4131-41. [PMID: 23992309 DOI: 10.2174/09298673113209990248] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
291 Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542-53. [PMID: 24513805 DOI: 10.1038/ajg.2014.11] [Cited by in Crossref: 305] [Cited by in F6Publishing: 312] [Article Influence: 33.9] [Reference Citation Analysis]
292 Tanase AM, Dumitrascu T, Dima S, Grigorie R, Marchio A, Pineau P, Popescu I. Influence of hepatitis viruses on clinicopathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2014;13:162-72. [PMID: 24686543 DOI: 10.1016/s1499-3872(14)60026-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
293 Chang JM, Huang CF, Chen SC, Dai CY, Yeh ML, Huang JF, Kuo HT, Chuang WL, Yu ML, Hwang SJ, Chen HC. Discrepancy between serological and virological analysis of viral hepatitis in hemodialysis patients. Int J Med Sci 2014;11:436-41. [PMID: 24688305 DOI: 10.7150/ijms.8265] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
294 Zou C, Li Y, Cao Y, Zhang J, Jiang J, Sheng Y, Wang S, Huang A, Tang H. Up-regulated MicroRNA-181a induces carcinogenesis in hepatitis B virus-related hepatocellular carcinoma by targeting E2F5. BMC Cancer. 2014;14:97. [PMID: 24529171 DOI: 10.1186/1471-2407-14-97] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
295 Gao S, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R, Xiao H. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. Cancer Cell. 2013;24:725-737. [PMID: 24332041 DOI: 10.1016/j.ccr.2013.11.005] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
296 Vineis P, Wild CP. Global cancer patterns: causes and prevention. The Lancet 2014;383:549-57. [DOI: 10.1016/s0140-6736(13)62224-2] [Cited by in Crossref: 344] [Cited by in F6Publishing: 371] [Article Influence: 38.2] [Reference Citation Analysis]
297 Fasullo M, Smith A, Egner P, Cera C. Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae. Mutat Res Genet Toxicol Environ Mutagen 2014;761:18-26. [PMID: 24472830 DOI: 10.1016/j.mrgentox.2014.01.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
298 Mao Y, Zhang J, Hou L, Cui X. The effect of beta-elemene on alpha-tubulin polymerization in human hepatoma HepG2 cells. Chin J Cancer Res 2013;25:770-6. [PMID: 24385707 DOI: 10.3978/j.issn.1000-9604.2013.12.12] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
299 Sanders JA, Gruppuso PA. Hepatic, Pancreatic and Biliary Cancers. Translation and Its Regulation in Cancer Biology and Medicine 2014. [DOI: 10.1007/978-94-017-9078-9_30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
300 Thomas London W. Liver Cancer: Etiology and Prevention☆. Reference Module in Biomedical Sciences 2014. [DOI: 10.1016/b978-0-12-801238-3.04380-4] [Reference Citation Analysis]
301 Sellner J, Steiner I. Neurologic complications of hepatic viruses. Handb Clin Neurol 2014;123:647-61. [PMID: 25015509 DOI: 10.1016/B978-0-444-53488-0.00031-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
302 Zhang Q, Bai XL, Chen W, Ma T, Liu H, Zhang Y, Hu XJ, Liang TB; Cochrane Hepato-Biliary Group. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010897] [Reference Citation Analysis]
303 Palmieri VO, Santovito D, Margari F, Lozupone M, Minerva F, Di Gennaro C, Todarello O, Palasciano G. Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. Clin Exp Med. 2015;15:65-72. [PMID: 24323278 DOI: 10.1007/s10238-013-0267-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
304 Loomba R, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL–HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013;11:1636-45.e1-3. [PMID: 23669307 DOI: 10.1016/j.cgh.2013.04.043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 6.1] [Reference Citation Analysis]
305 Guo J, Ma Q, Zhou X, Fan P, Shan T, Miao D. Inactivation of p27kip1 promotes chemical hepatocarcinogenesis through enhancing inflammatory cytokine secretion and STAT3 signaling activation. J Cell Physiol 2013;228:1967-76. [PMID: 23460367 DOI: 10.1002/jcp.24357] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
306 do Nascimento JH, Epifanio M, Soder RB, Baldisserotto M. MRI-diagnosed nonalcoholic fatty liver disease is correlated to insulin resistance in adolescents. Acad Radiol 2013;20:1436-42. [PMID: 24119357 DOI: 10.1016/j.acra.2013.08.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
307 Liu F, Li GJ, Wu JZ, Wu JL, Chen WQ, Ma SS, Hu DF, Ning QY, Pang Y. Association between HLA-DRB1*08/16 alleles and familial aggregation of hepatocellular carcinoma in Guangxi. Shijie Huaren Xiaohua Zazhi 2013; 21(27): 2854-2859 [DOI: 10.11569/wcjd.v21.i27.2854] [Reference Citation Analysis]
308 El Idrissi M, Hervieu V, Merle P, Mortreux F, Wattel E. Cause-specific telomere factors deregulation in hepatocellular carcinoma. J Exp Clin Cancer Res. 2013;32:64. [PMID: 24020493 DOI: 10.1186/1756-9966-32-64] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
309 Wan J, Huang M, Zhao H, Wang C, Zhao X, Jiang X, Bian S, He Y, Gao Y. A novel tetranucleotide repeat polymorphism within KCNQ1OT1 confers risk for hepatocellular carcinoma. DNA Cell Biol 2013;32:628-34. [PMID: 23984860 DOI: 10.1089/dna.2013.2118] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
310 Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29:558-568. [PMID: 23937321 DOI: 10.3109/02656736.2013.821528] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
311 Wang C, Zhao H, Zhao X, Wan J, Wang D, Bi W, Jiang X, Gao Y. Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma. Tumour Biol 2014;35:295-301. [PMID: 23918301 DOI: 10.1007/s13277-013-1039-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
312 Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:1314-21. [PMID: 23752878 DOI: 10.1038/ajg.2013.160] [Cited by in Crossref: 228] [Cited by in F6Publishing: 231] [Article Influence: 22.8] [Reference Citation Analysis]
313 Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int 2013;7 Suppl 2:823-32. [PMID: 26202297 DOI: 10.1007/s12072-013-9453-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
314 Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383:49-58. [PMID: 23842624 DOI: 10.1007/s11010-013-1753-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
315 Schirmacher P, Calvisi DF. Molecular diagnostic algorithms in hepatocellular carcinoma: dead-end street or light at the end of the tunnel? Gastroenterology 2013;145:49-53. [PMID: 23727497 DOI: 10.1053/j.gastro.2013.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
316 Brennan BJ, Xu ZX, Grippo JF. Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 2013;75:497-506. [PMID: 22765278 DOI: 10.1111/j.1365-2125.2012.04373.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
317 Choi JW, Lee JM, Kim SJ, Yoon J, Baek JH, Han JK, Choi BI. Hepatocellular Carcinoma: Imaging Patterns on Gadoxetic Acid–enhanced MR Images and Their Value as an Imaging Biomarker. Radiology 2013;267:776-86. [DOI: 10.1148/radiol.13120775] [Cited by in Crossref: 129] [Cited by in F6Publishing: 135] [Article Influence: 12.9] [Reference Citation Analysis]
318 Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology 2013;57:2338-45. [PMID: 23325627 DOI: 10.1002/hep.26264] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
319 Li Z, Yuan W, Ning S, Li J, Zhai W, Zhang S. Role of leptin receptor (LEPR) gene polymorphisms and haplotypes in susceptibility to hepatocellular carcinoma in subjects with chronic hepatitis B virus infection. Mol Diagn Ther. 2012;16:383-388. [PMID: 23090836 DOI: 10.1007/s40291-012-0008-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
320 Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol 2013; 19(16): 2449-2455 [PMID: 23674845 DOI: 10.3748/wjg.v19.i16.2449] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 48] [Article Influence: 3.8] [Reference Citation Analysis]
321 Fingas CD, Altinbas A, Schlattjan M, Beilfuss A, Sowa JP, Sydor S, Bechmann LP, Ertle J, Akkiz H, Herzer K, Paul A, Gerken G, Baba HA, Canbay A. Expression of apoptosis- and vitamin D pathway-related genes in hepatocellular carcinoma. Digestion 2013;87:176-81. [PMID: 23635474 DOI: 10.1159/000348441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
322 Lo PH, Urabe Y, Kumar V, Tanikawa C, Koike K, Kato N, Miki D, Chayama K, Kubo M, Nakamura Y, Matsuda K. Identification of a functional variant in the MICA promoter which regulates MICA expression and increases HCV-related hepatocellular carcinoma risk. PLoS One 2013;8:e61279. [PMID: 23593449 DOI: 10.1371/journal.pone.0061279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
323 Parikh N, Nonnemacher MR, Pirrone V, Block T, Mehta A, Wigdahl B. Substance abuse, HIV-1 and hepatitis. Curr HIV Res 2012;10:557-71. [PMID: 22973853 DOI: 10.2174/157016212803306023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
324 Schütte K, Kipper M, Kahl S, Bornschein J, Götze T, Adolf D, Arend J, Seidensticker R, Lippert H, Ricke J, Malfertheiner P. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion 2013;87:147-59. [PMID: 23548687 DOI: 10.1159/000346743] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
325 De P, Dryer D, Otterstatter MC, Semenciw R. Canadian trends in liver cancer: a brief clinical and epidemiologic overview. Curr Oncol 2013;20:e40-3. [PMID: 23443230 DOI: 10.3747/co.20.1190] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
326 Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24:1667-1674. [PMID: 23378539 DOI: 10.1093/annonc/mds652] [Cited by in Crossref: 85] [Cited by in F6Publishing: 95] [Article Influence: 8.5] [Reference Citation Analysis]
327 Palliyaguru DL, Wu F. Global geographical overlap of aflatoxin and hepatitis C: controlling risk factors for liver cancer worldwide. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2013;30:534-40. [PMID: 23281740 DOI: 10.1080/19440049.2012.751630] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
328 Cabrera R, Limaye AR, Horne P, Mills R, Soldevila-Pico C, Clark V, Morelli G, Firpi R, Nelson DR. The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37:91-7. [PMID: 23094860 DOI: 10.1111/apt.12098] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
329 Bellentani S, Tiribelli C, Bedogni G. Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. Alcohol, Nutrition, and Health Consequences 2013. [DOI: 10.1007/978-1-62703-047-2_38] [Reference Citation Analysis]
330 Alkhouri N, Mccullough A. Obesity, Inflammation, Nonalcoholic Fatty Liver Disease, and Hepatocellular Carcinoma. Obesity, Inflammation and Cancer 2013. [DOI: 10.1007/978-1-4614-6819-6_9] [Reference Citation Analysis]
331 Zhu Q, Li J, Yan JJ, Huang L, Wu MC, Yan YQ. Predictors and clinical outcomes for spontaneous rupture of hepatocellular carcinoma. World J Gastroenterol 2012; 18(48): 7302-7307 [PMID: 23326137 DOI: 10.3748/wjg.v18.i48.7302] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 73] [Article Influence: 5.8] [Reference Citation Analysis]
332 London WT, McGlynn KA. Can propranalol prevent hepatocellular carcinoma? Cancer Prev Res (Phila) 2012;5:989-91. [PMID: 22869451 DOI: 10.1158/1940-6207.CAPR-12-0247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
333 Aguiar e Silva MA, Vechetti-junior IJ, Nascimento AFD, Furtado KS, Azevedo L, Ribeiro DA, Barbisan LF. Effects of swim training on liver carcinogenesis in male Wistar rats fed a low-fat or high-fat diet. Appl Physiol Nutr Metab 2012;37:1101-9. [DOI: 10.1139/h2012-129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
334 Sahasrabuddhe VV, Gunja MZ, Graubard BI, Trabert B, Schwartz LM, Park Y, Hollenbeck AR, Freedman ND, McGlynn KA. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104:1808-1814. [PMID: 23197492 DOI: 10.1093/jnci/djs452] [Cited by in Crossref: 151] [Cited by in F6Publishing: 163] [Article Influence: 13.7] [Reference Citation Analysis]
335 Maletzki C, Bodammer P, Breitrück A, Kerkhoff C. S100 proteins as diagnostic and prognostic markers in colorectal and hepatocellular carcinoma. Hepat Mon 2012;12:e7240. [PMID: 23166536 DOI: 10.5812/hepatmon.7240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
336 Caifeng L, Jing L, Liang H, Yiqun Y. Reactivation of hepatitis C virus replication in a patient undergoing hepatectomy for hepatocellular carcinoma. Journal of Medical Colleges of PLA 2012;27:306-310. [DOI: 10.1016/s1000-1948(12)60040-9] [Reference Citation Analysis]
337 Peyrou M, Ramadori P, Bourgoin L, Foti M. PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs. PPAR Res 2012;2012:757803. [PMID: 23024649 DOI: 10.1155/2012/757803] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
338 Rossi C, Shrier I, Marshall L, Cnossen S, Schwartzman K, Klein MB, Schwarzer G, Greenaway C. Seroprevalence of chronic hepatitis B virus infection and prior immunity in immigrants and refugees: a systematic review and meta-analysis. PLoS One. 2012;7:e44611. [PMID: 22957088 DOI: 10.1371/journal.pone.0044611] [Cited by in Crossref: 99] [Cited by in F6Publishing: 106] [Article Influence: 9.0] [Reference Citation Analysis]
339 Zhong DN, Ning QY, Wu JZ, Zang N, Wu JL, Hu DF, Luo SY, Huang AC, Li LL, Li GJ. Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci. 2012;103:1833-1838. [PMID: 22726459 DOI: 10.1111/j.1349-7006.2012.02368.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
340 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 31] [Article Influence: 0.5] [Reference Citation Analysis]
341 Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118:6226-6233. [PMID: 22736272 DOI: 10.1002/cncr.27694] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
342 Qian Z, Jianjun Y, Xianghua Z, Jie C, Liang H, Jing L, Jun S, Feiguo Z, Yiqun Y. Long-term survival for spontaneous rupture of hepatocellular carcinoma treated with hepatectomy. Journal of Medical Colleges of PLA 2012;27:161-182. [DOI: 10.1016/s1000-1948(12)60017-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
343 Alisi A, Baffet G. Self-renewal of tumor-initiating cells: what's new about hepatocellular carcinoma? Gastroenterology 2012;142:1414-6. [PMID: 22542831 DOI: 10.1053/j.gastro.2012.04.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
344 Patil A, Khanna N. Novel membrane extraction procedure for the purification of hepatitis B surface antigen from Pichia pastoris. Journal of Chromatography B 2012;898:7-14. [DOI: 10.1016/j.jchromb.2012.03.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
345 Meredith I, Sarfati D, Ikeda T, Blakely T. Cancer in Pacific people in New Zealand. Cancer Causes Control 2012;23:1173-84. [PMID: 22618362 DOI: 10.1007/s10552-012-9986-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
346 Wang CJ, Xiao CW, You TG, Zheng YX, Gao W, Zhou ZQ, Chen J, Xue XB, Fan J, Zhang H. Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer 2012;11:31. [PMID: 22569271 DOI: 10.1186/1476-4598-11-31] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
347 Brennan BJ, Morcos PN, Wang K, Blotner SD, Morrison R, Hagedorn CH, Marbury TC, Sulkowski M, Grippo JF. The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Aliment Pharmacol Ther 2012;35:1209-20. [PMID: 22469033 DOI: 10.1111/j.1365-2036.2012.05079.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
348 Ramirez AG, Weiss NS, Holden AE, Suarez L, Cooper SP, Munoz E, Naylor SL. Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research. PLoS One. 2012;7:e35573. [PMID: 22530052 DOI: 10.1371/journal.pone.0035573] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
349 Boregowda RK, Adams C, Hu J. TP-RT domain interactions of duck hepatitis B virus reverse transcriptase in cis and in trans during protein-primed initiation of DNA synthesis in vitro. J Virol 2012;86:6522-36. [PMID: 22514346 DOI: 10.1128/JVI.00086-12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
350 Mcglynn KA, London WT. International Liver Cancer Incidence Trends—Letter. Cancer Epidemiology, Biomarkers & Prevention 2012;21:384-385. [DOI: 10.1158/1055-9965.epi-11-1102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
351 Yu JI, Park HC, Lim DH, Park W, Yoo BC, Paik SW, Koh KC, Lee JH. Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci. 2011;26:1014-1022. [PMID: 21860551 DOI: 10.3346/jkms.2011.26.8.1014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]